Search results for "Progress"

showing 10 items of 1620 documents

Early and late clinical landmarks of corneal dystrophies

2020

Abstract Corneal dystrophies (CDs) represent a heterogenous group of genetic diseases (Lisch and Weiss, 2019). The International Committee of Classification of Corneal Dystrophies (IC3D) distinguishes between 22 distinct forms of corneal dystrophy (CD) which are predominantly autosomal dominant, although autosomal recessive and X-chromosomal dominant and recessive patterns do exist. A detailed corneal examination of as many affected family members as possible can show the phenotypic differences of the various generations. There are few publications which describe the different CDs with regard to the early and late phenotypes. According to early and late phenotype, three types of CD are gene…

Corneal Dystrophies HereditaryGeneticsTime Factorsgenetic structuresDystrophyCorneal dystrophyLate onsetBiologymedicine.diseasePhenotypeeye diseasesSensory SystemsCorneaCellular and Molecular NeuroscienceOphthalmologyPhenotypeRecessive inheritanceDisease ProgressionmedicineHumanssense organsGeneExperimental Eye Research
researchProduct

Changing Perceptions of Multiculturalism in the British Public Sphere

2017

This paper is devoted to the examination of the evolution of the uses of the term multiculturalism in a corpus of selected speeches by prominent British politicians, officials and diplomats in the United Kingdom within the decade 2001–2011. Britain is considered to be one of Europe’s most multicultural countries and there was a time when its government took pride in its pro-integration policies. That is why within the elite discourses of the Labour governments of the late 1990s, multiculturalism had overwhelmingly positive connotations: it was associated with new opportunities, strength, enrichment, social progress and economic success. However, over the course of the 2000s there was much d…

Critical discourse analysisDiscourse analysisPolitical economyPolitical scienceMulticulturalismmedia_common.quotation_subjectEliteImmigrationNational identityPublic spherePublic administrationSocial progressmedia_common
researchProduct

Targeted Therapies for Non-Small Cell Lung Cancer

2015

The discovery of new oncogenic driver mutations and the clinical development of targeted therapies have completely changed the paradigm treatment of non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib, ALK-inhibitors, crizotinib, and ceritinib, have been already approved for clinical use, benefiting many patients whose tumors harbor, respectively, EGFR or EML4-ALK molecular alterations. However, despite an initial benefit, tumor progression inevitably occurs, due to the development of acquired resistance to the targeted treatments. Several mechanisms of resistance have been identified, such as the seco…

CrizotinibbiologyCeritinibbusiness.industryAfatinibmedicine.diseaserespiratory tract diseasesGefitinibTumor progressionmedicineCancer researchbiology.proteinErlotinibEpidermal growth factor receptorLung cancerbusinessmedicine.drug
researchProduct

Prognostic Value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 Immunoreactivity in pT1 G3 Urothelial Bladder Carcinomas

2001

pT1 G3 bladder carcinomas are heterogeneous with respect to tumor recurrence and progression. Whereas some urologists treat these carcinomas by repeated transurethral resections often followed by intravesical chemotherapy or BCG instillation, others recommend cystectomy after tumor recurrence or early cystectomy after the initial diagnosis. Our goal was to determine the prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in these tumors. There were 30 patients with a new histopathological diagnosis of pT1 G3 urothelial carcinoma based on a transurethral resection specimen. Representative sections of these specimens were examined for the above markers. All patients…

Cyclin-Dependent Kinase Inhibitor p21medicine.medical_specialtyPathologyTime FactorsTumor suppressor genemedicine.medical_treatmentBcl 2 baxUrologyDisease-Free SurvivalCystectomyPredictive Value of TestsCyclinsProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasm InvasivenessRetrospective Studiesbcl-2-Associated X ProteinCarcinoma Transitional CellUrinary bladderBladder cancerbiologyMembrane ProteinsGeneral MedicinePrognosismedicine.diseaseImmunohistochemistrySurvival RateKi-67 Antigenbcl-2 Homologous Antagonist-Killer Proteinmedicine.anatomical_structureTransitional cell carcinomaProto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsTumor progressionKi-67biology.proteinTumor Suppressor Protein p53Follow-Up StudiesTumor Biology
researchProduct

Myc Promoter-Binding Protein-1 (MBP-1) Is a Novel Potential Prognostic Marker in Invasive Ductal Breast Carcinoma

2010

BackgroundAlpha-enolase is a glycolytic enzyme that catalyses the formation of phosphoenolpyruvate in the cell cytoplasm. α-Enolase and the predominantly nuclear Myc promoter-binding protein-1 (MBP-1) originate from a single gene through the alternative use of translational starting sites. MBP-1 binds to the P2 c-myc promoter and competes with TATA-box binding protein (TBP) to suppress gene transcription. Although several studies have shown an antiproliferative effect of MBP-1 overexpression on several human cancer cells, to date detailed observations of α-enolase and MBP-1 relative expression in primary tumors versus normal tissues and their correlation with clinicopathological features ha…

CytoplasmAlpha-enolasePROGRESSIONAged 80 and overRegulation of gene expressionMultidisciplinaryQRGenetics and Genomics/Gene ExpressionMiddle AgedPrognosisPathology/Molecular PathologyNUDE-MICETransport proteinCarcinoma DuctalDNA-Binding ProteinsGene Expression Regulation NeoplasticProtein Transportmedicine.anatomical_structureGLYCOLYTIC ENZYMEOncology/Breast CancerMedicineCELL LUNG-CANCER; ALPHA-ENOLASE; PROTEOMIC ANALYSIS; GLYCOLYTIC ENZYME; NUDE-MICE; GENE; IDENTIFICATION; PROGRESSION; EXPRESSION; METASTASESFemalePROTEOMIC ANALYSISEnolase MBP-1 Breast cancer ImmunohistochemistryResearch ArticleAdultEXPRESSIONScienceCELL LUNG-CANCERBreast NeoplasmsBiologyDNA-binding proteinBiomarkers TumormedicineHumansNeoplasm InvasivenessGeneAgedCell NucleusIDENTIFICATIONBinding proteinALPHA-ENOLASEGENEMolecular biologySettore BIO/18 - GeneticaCell nucleusMETASTASESCytoplasmPhosphopyruvate Hydratasebiology.proteinPLoS ONE
researchProduct

Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H…

1998

The effects of 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 (a cAMP-dependent protein kinase and protein kinase C inhibitor), n-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 (a cAMP- and cGMP-dependent protein kinase inhibitor) and indomethacin (IND, a cyclooxygenase inhibitor) on both the spontaneous metastatic ability of 3LL (Lewis lung carcinoma) tumor cells and anti-tumor host response were studied. The study of tumor progression showed that H-7 and H-8 (2 mg kg(-1) day(-1) , i.p., for 8 days) significantly reduced the mean number of metastases (0.8 +/- 0.2 and 1.0 +/- 0.7, respectively, P0.05) with respect to the number of lung metastases (4.2 +/- 2.1) observed in the con…

Cytotoxicity ImmunologicMalemedicine.medical_specialtymedicine.drug_classIndomethacinCarcinoma Lewis LungMiceInternal medicine1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsCyclooxygenase InhibitorsLymphocytesEnzyme InhibitorsNeoplasm MetastasisCytotoxicityProtein kinase AProtein kinase CPharmacologybiologyLewis lung carcinomaProtein kinase inhibitorIsoquinolinesMice Inbred C57BLEndocrinologyEnzyme inhibitorTumor progressionbiology.proteinCancer researchDisease ProgressionLeukocytes MononuclearCyclooxygenaseCell DivisionNeoplasm TransplantationSpleenEuropean journal of pharmacology
researchProduct

Eurofusion-DEMO Divertor - Cassette Design and Integration

2020

International audience; The Eurofusion-DEMO design will complete the Pre Conceptual Design phase (PCD) with a PCD Gate, named G1, scheduled to take place in Q4 2020 that will focus on assessing the feasibility of the plant and its main components prior to entering into the Conceptual Design phase. In the paper first an overview is given of the Eurofusion-DEMO Divertor Assembly including design and interface description, systems and functional requirements, load specification, system classification, manufacturing procedures and cost estimate. Then critical issues are discussed and potential design solutions are proposed, e.g.:- Neutron material damage limits of the different (structural) mat…

DEMO; Divertor; CAD DesignMaterials sciencePassive coolingNuclear engineeringPort (circuit theory)01 natural sciences7. Clean energy010305 fluids & plasmas[SPI]Engineering Sciences [physics]DivertorConceptual design0103 physical sciencesDEMO fusion reactorGeneral Materials ScienceCAD Design010306 general physicsDEMOnuclear fusionSettore ING-IND/19 - Impianti NucleariCivil and Structural Engineeringelectromagnetic computationToroidNuclear heatingSeparatrixMechanical EngineeringDivertornuclear fusion plasma control electromagnetic computationNuclear Energy and EngineeringTUNGSTEN/EUROFER COATING SYSTEM CONCEPTUAL DESIGN COOLING CIRCUIT PROGRESS HCLLplasma controlHigh heat
researchProduct

Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas.

2003

Apurinic/apyrimidinic endonuclease (APE alias Ref-1) is a key enzyme in the base excision repair pathway. Besides its function in DNA repair, APE serves to maintain several transcription factors in an active reduced state such as c-Fos, c-Jun, NF-kappaB, p53 and HIF-1alpha, all of which have been shown to play a role in tumorigenesis. Because of the importance of APE in maintaining genomic stability and gene regulation, we examined whether APE expression is associated with survival and histopathological parameters of patients with ovarian cancer.Tissue sections of primary epithelial ovarian carcinomas from 141 patients were immunostained using a monoclonal antibody directed against APE.Nucl…

DNA repairvirusesBiologymedicine.disease_causestomatognathic systemOvarian carcinomamedicineBiomarkers TumorDNA-(Apurinic or Apyrimidinic Site) LyaseHumansNeoplasm StagingRegulation of gene expressionCell NucleusOvarian NeoplasmsObstetrics and Gynecologysocial sciencesBase excision repairmedicine.diseasePrognosisMolecular biologyImmunohistochemistrybody regionsSurvival RateOncologyTumor progressionCancer researchDisease ProgressionImmunohistochemistryFemaleOvarian cancerCarcinogenesisGynecologic oncology
researchProduct

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression al…

2002

AbstractGenomic aberrations in a series of paired biopsy samples from patients who presented initially with follicle center lymphoma (FCL) and subsequently transformed to diffuse large B-cell lymphoma (DLBCL) were measured by array comparative genomic hybridization (CGH). The consequences of these aberrations on gene expression were determined by comparison with expression analysis on these specimens using cDNA microarrays. A heterogeneous pattern of acquired genomic abnormalities was observed upon transformation, some of which were recurrent in small subsets of patients. Some of the genomic aberration acquired upon transformation, such as gain/amplification of 1q21-q24, 2p16 (REL/BCL11A ge…

DNA ComplementaryImmunologyFollicular lymphomaLocus (genetics)BiologyAllelic ImbalanceBiochemistryGene duplicationmedicineChromosomes HumanHumansGeneLymphoma FollicularOligonucleotide Array Sequence AnalysisGeneticsChromosome AberrationsGene Expression ProfilingGene AmplificationCell BiologyHematologyDNA Neoplasmmedicine.diseaseBCL6Gene Expression Regulation NeoplasticCell Transformation NeoplasticDisease ProgressionLymphoma Large B-Cell DiffuseDNA microarrayChromosome DeletionDiffuse large B-cell lymphomaComparative genomic hybridizationBlood
researchProduct

A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis.

2020

DermatologyBiologymedicine.diseaseSkin DiseasesReceptor Platelet-Derived Growth Factor betaHistiocytosisGermline mutationChronic diseaseHereditary progressive mucinous histiocytosisChronic DiseaseCancer researchmedicinePlatelet-Derived Growth Factor Receptor BetaHumansPlatelet-Derived Growth Factor BetaReceptorGeneHistiocytosisGerm-Line Mutation
researchProduct